LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months ...
MedPage Today on MSN
Benefit of Dual Antiplatelet Therapy Murky in Valve-in-Valve Intervention
The interest in dual antiplatelet therapy after valve-in-valve transcatheter aortic valve intervention stems from the higher thrombotic risk associated with reintervention for a bioprosthetic valve ...
On Wednesday, 2797 stocks advanced, 1360 declined and 146 remained unchanged on Bombay Stock Exchange with advance decline ...
Discover Daiichi Sankyo's Q2 2024 earnings, updated revenue forecasts, oncology pipeline advances, and global partnerships.
Bioxodes appoints industry veteran Philippe Monteyne as chairman as it accelerates late-stage development of breakthrough stroke candidateFormer GSK and Sanofi executive, led Cervarix® development and ...
DelveInsight’s, “Buerger’s Disease - Pipeline Insight, 2025,” report provides comprehensive insights about 3+ companies and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback